{
    "clinical_study": {
        "@rank": "151336", 
        "arm_group": [
            {
                "arm_group_label": "Oprozomib, Lenalidomide and Dexamethasone (ORd)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive oprozomib administered orally, once daily on Days 1-5 and on Days 15-19 in combination with lenalidomide at a dose of 25 mg on Days 1-21, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles"
            }, 
            {
                "arm_group_label": "Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive oprozomib administered orally, once daily on Days 1-5 and on Days 15-19 in combination with oral cyclophosphamide at a dose of 300 mg/m2 on Days 1, 8, and 15, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 1b:\n\n        -  To establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone\n           administered in combination with lenalidomide or oral cyclophosphamide\n\n        -  To evaluate the safety and tolerability of oprozomib and dexamethasone administered in\n           combination with lenalidomide  or oral cyclophosphamide\n\n      Phase 2:\n\n        -  To estimate the overall response rate (ORR) and complete response rate (CRR)\n\n        -  To evaluate the safety and tolerability of oprozomib and dexamethasone administered in\n           combination with lenalidomide  or oral cyclophosphamide\n\n      Secondary Objectives:\n\n        -  To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and\n           variability in these estimates when administered in combination with dexamethasone and\n           lenalidomide or oral cyclophosphamide\n\n        -  To estimate the duration of response (DOR)\n\n        -  To estimate progression-free survival (PFS)"
        }, 
        "brief_title": "Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma", 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Newly diagnosed, symptomatic multiple myeloma patients for whom treatment is\n             indicated per the NCCN guidelines, and for whom a hematopoietic stem cell transplant\n             is not planned or scheduled during the study or are considered ineligible for\n             hematopoietic stem cell transplant, with measurable disease\n\n          -  Creatinine clearance of > 50 mL/min (measured or calculated using the Cockcroft and\n             Gault formula)\n\n        Key Exclusion Criteria:\n\n          -  Any prior systemic antimyeloma therapy except oral steroids (dexamethasone up to a\n             total dose of 160 mg or equivalent within 14 days prior to the first dose of study\n             treatment). Use of topical or inhaled steroids is acceptable\n\n          -  Radiation therapy within 2 weeks prior to first dose\n\n          -  Major surgery within 3 weeks prior to first dose\n\n          -  Active infection requiring systemic antibiotics, antivirals, or antifungals within 2\n             weeks prior to first dose\n\n          -  Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of first\n             dose\n\n          -  Other malignancy within the past 3 years except those considered cured by surgical\n             resection including some cases of: with the exception of adequately treated basal or\n             squamous cell carcinoma of the skin, squamous cell skin cancer, thyroid cancer,\n             carcinoma in situ of the breast or cervix, carcinoma in situ of the breast, prostate\n             cancer with Gleason Score 6 or less with stable prostate specific antigen levels., or\n             cancer considered cured by surgical resection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "118", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881789", 
            "org_study_id": "OPZ003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Oprozomib, Lenalidomide and Dexamethasone (ORd)", 
                    "Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)"
                ], 
                "description": "Subjects will receive Oprozomib Tablets (hereafter referred to as oprozomib) administered orally, once daily on Days 1-5 and on Days 15-19 of 28 day cycles", 
                "intervention_name": "Oprozomib", 
                "intervention_type": "Drug", 
                "other_name": "Oprozomib tablets"
            }, 
            {
                "arm_group_label": "Oprozomib, Lenalidomide and Dexamethasone (ORd)", 
                "description": "Subjects will receive lenalidomide 25 mg on Days 1-21 of 28 day cycles", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "Revlimid"
            }, 
            {
                "arm_group_label": [
                    "Oprozomib, Lenalidomide and Dexamethasone (ORd)", 
                    "Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)"
                ], 
                "description": "Subjects will receive dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28 day cycles", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)", 
                "description": "Subjects will receive cyclophophamide 300 mg/m2 on Days 1, 8 and 15 of 28 day cycles", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cytoxan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Thalidomide", 
                "Lenalidomide", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "multiple myeloma", 
            "proteasome inhibitor", 
            "oprozomib", 
            "orpozomib tablets"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Burbank", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Providence St. Joseph's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Colorado Blood Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Indiana University Health Melvin and Bren Simon Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Cleveland Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "University of Texas M.D. Anderson Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "Froedtert Hospital and the Medical College of Wisconsin"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma", 
        "overall_contact": {
            "email": "medinfo@onyx.com", 
            "last_name": "Onyx Medical Information", 
            "phone": "877-669-9121"
        }, 
        "overall_official": {
            "affiliation": "Onyx Therapeutics, Inc.", 
            "last_name": "Paula O'Connor, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "To establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide  or oral cyclophosphamide", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "measure": "To estimate the overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "14 months"
            }, 
            {
                "measure": "To estimate the complete response rate (CRR)", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881789"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Based on plasma concentration of oprozomib and its metabolites at various time points", 
                "measure": "To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with lenalidomide and dexamethasone, or oral cyclophosphamide and dexamethasone", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "To estimate the duration of response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }, 
            {
                "measure": "To estimate progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }
        ], 
        "source": "Onyx Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}